Ipsen Sa · EURONEXT:IPN
Ipsen Sa — Q3 2026 Earnings Presentation
20 slides from Ipsen Sa's earnings presentation, Oct 22, 2026
Slide 1: Q3 2026 update
Q3 2026 update 22 October 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Speakers
Speakers Presentation Joining for Q&A Aymeric Le Chatelier Chief Financial Officer Christelle Huguet Head of R&D David Loew Chief Executive Officer
Slide 4: Today’s highlights
Today’s highlights Financial Performance Q3 sales growth of +26.7% at CER1 YTD sales growth of +24.6% at CER • Core Portfolio2: +24.2% • Somatuline®: +25.5% Upgraded 2026 guidance • Total sales growth around +23.0% at CER (prior guidance: > +20.0%) • Core operating margin around 39.0% of total sales
Slide 5: Q3 & YTD sales performance
Q3 & YTD sales performance Q3 2026 YTD 2026 €m % change €m % change Oncology 745 17.7% 2,197 16.3% Rare Disease 194 88.6% 498 100.1% Neuroscience 235 23.1% 669 18.8% Total Sales 1,174 26.7% 3,364 24.6% Core Portfolio1 Sales 793 23.3% 2,297 24.2% Growth at constant exchange rates; 1 All medicines exc
Slide 6: YTD 2026 sales growth by key medicine
YTD 2026 sales growth by key medicine Neuroscience Oncology +18.8% +16.3% €416m €1,067m Aesthetics +25.6% +25.5% 669 2,197 €243m €523m Therapeutics +9.2% +15.6% €3,364m +24.6% 498 €426m Rare Disease +5.0% €283m +100.1% +170.8% €147m +0.0% €189m +43.8% €25m Growth at constant exchange rates 6
Slide 7: Upgraded FY 2026 guidance
Upgraded FY 2026 guidance Total sales growth Core operating margin ~+ 23.0% ~39.0% at constant exchange rates of total sales (prior >+20.0%) (prior >37.0%) Impact of around -0.5% from currencies1 1 Based on current average exchange rates in October 2026 7
Slide 8: Advancing late-stage assets toward blockbuster potential
Advancing late-stage assets toward blockbuster potential ONCOLOGY RARE DISEASE NEUROSCIENCE Navtemadlin Iqirvo1 Dysport Tx2 • Myelofibrosis • PBC • Migraine • Ph. III POIESIS • Ph. III ELSPIRE • Ph. III C/E-BEOND • Readout 2027 • Reg. Filing 2026 • Reg. Filing 2026 Potravitug Corabotase IPN60340 • A
Slide 9: R&D pipeline across three therapeutic areas
R&D pipeline across three therapeutic areas Asset MoA Phase I Phase II Phase III Regulatory Tovorafenib Type II RAFi FIREFLY-21: 1L pLGG ONCOLOGY Navtemadlin MDM2i POIESIS: Myelofibrosis IPN603402 BTN3A T-Cell Activator EVICTION-3: 1L Unfit AML IPN60300 ADC Solid Tumors IPN01203 TCA Solid Tumors Iqi
Slide 10: Major upcoming milestones
Major upcoming milestones Asset MoA Stage 2026 2027 2028 Navtemadlin MDM2i Phase III POIESIS: Myelofibrosis Tovorafenib Type II RAFi Phase III FIREFLY-21: 1L pLGG Corabotase RNITM Phase II LANTIMA: AUL (Tx) Corabotase RNITM Phase II MERANTI: Migraine (Tx) Corabotase RNITM Phase II CATALPA: Cervical
Slide 11: Key takeaways
Key takeaways Executing on 2026 priorities Delivering Strong Financials • Solid double-digit sales growth momentum • Further upgraded full-year guidance Expanding Portfolio of Late-Stage Assets • Preparing for the next wave of major launches • Multiple blockbuster-potential catalysts over the next 1
Slide 12: Questions
SIPSEN Questions 12
Slide 13: Appendix
Appendix SIPSEN
Slide 14: Currency impact YTD 2026 sales
Currency impact YTD 2026 sales FX negative impact of -1.6 pts YTD 2026 sales by currency Average rate changes (YTD 2026 vs. YTD 2025) BRL: 5.98 AUD : 1.65 MXN: 20.20 Other 23.3% +5% +5% +7% 31.3% EUR -22% -4% -3% USD: 1.16 CNY 3.2% 4.4% GBP 37.7% TRY: 53.13 USD USD 14
Slide 15: Oncology: key ongoing clinical-trial highlights
Oncology Key ongoing clinical-trial highlights Primary Trial Indication Patients Design Status Endpoint(s) Tovorafenib Tovorafenib FIREFLY-2 Active, not 1L pLGG 418 or ORR Phase III recruiting1,2 SoC chemotherapy NCT05566795 Spleen volume Navtemadlin reduction (SVR35) Navtemadlin + Ruxolitinib POIES
Slide 16: Rare Disease: key ongoing clinical-trial highlights
Rare Disease Key ongoing clinical-trial highlights Primary Trial Indication Patients Design Status Endpoint(s) Iqirvo Percentage of Iqirvo ELSPIRE1 participants with 2L PBC 92 or Completed2 Phase III normalization of ALP Placebo NCT06383403 levels Event-free survival : time from Elafibranor Elafibra
Slide 17: Neuroscience - Dysport
Neuroscience - Dysport Key ongoing clinical-trial highlights Primary Trial Indication Patients Design Status Endpoint(s) Dysport Two dosing regimes Change from baseline C-BEOND of Dysport Active, not Chronic migraine 759 in monthly migraine Phase III or recruiting1,2 days (MMD) NCT06047444 Placebo D
Slide 18: Neuroscience – corabotase
Neuroscience – corabotase Key ongoing clinical-trial highlights Primary Trial Indication Patients Design Status Endpoint(s) Corabotase Composite response of LAURITE 1 & 2 Corabotase 2-grade improvement Phase III Moderate to severe GL 1,600 or on SSA and ILA at Active, not recruiting1 NCT07427797 Pla
Slide 19: Investor Relations
Investor Relations Henry Wheeler Khalid Deojee Vice President, Investor Relations Senior Manager, Investor Relations +33 7 64 47 11 49 +33 6 66 01 95 26 henry.wheeler@ipsen.com khalid.deojee@ipsen.com
Slide 20: Thank You
Thank You Learn more about us